Andreas Agathangelidis is a post-doctoral researcher at the Institute of Applied Biosciences (INAB) at CERTH (Center for Research and Technology Hellas) where he focuses on the immunogenetics of B cell malignancies using novel, state-of-the-art NGS protocols and technologies. He began his scientific career at the Laboratory of Molecular Biology at the Hematology Clinic of the G. Papanicolaou Hospital in Thessaloniki, Greece, where he performed research in the context of his diploma thesis concerning the analysis of intraclonal diversity in patients with CLL. During his PhD, he engaged in various studies on the immunogenetics of B-cell malignancies, mainly CLL and mantle cell lymphoma (MCL), focusing on the role of antigens in disease pathogenesis. Throughout the same period, he also engaged in several immunoprofiling studies in B-malignancies, extending from partial IGHD-IGHJ gene rearrangements in CLL and the molecular subtyping of MCL based on the integration of immunogenetics, oncogenetics and immunophenotype. After his PhD, he joined the group of Professor Paolo Ghia for postdoc research focusing on the genetic background of MBL and CLL, gaining sufficient expertise in a series of methodologies, such as flow-cytometry, cell sorting of small B cell populations as well as state-of-the-art NGS techniques i.e. whole genome sequencing and targeted deep-sequencing (manuscript under consideration). During his post-doc studies in Milan, he continued to participate in many large, multi-institutional studies on CLL covering different aspects of the pathophysiology of this disease, from genetic drivers to immune signaling.
Tel. +30 2311 257 525